PRESCRIÇÃO DE FITOTERÁPICOS

COMO FAZER?
Prof. Leandro Medeiros
(@prof_leandromedeiros)

Fortaleza, 2016
 MAS AFINAL, QUE PRODUTOS SÃO
CONTEMPLADOS PELA FITOTERAPIA?
CARACTERIZANDO A FITOTERAPIA

Metabólitos
primários
(Nutrientes)

Vegetais

Metabólitos
secundários
(Fitonutrientes ou fitoquímicos)

Alonso, 2004
 CARACTERIZANDO A FITOTERAPIA
Milk Thistle 431

430 Milk Thistle

The effects of silymarin on biliary bile salt secretion have been

seen in studies in rats.(17) Intraperitoneal silymarin (25, 50, 100
430 Milk Thistle and 150 mg/kg/day) for five days induced a dose-dependent
increase in bile flow and bile salt secretion. Stimulation of bile
M salt secretion was mainly accounted for by an increase in the
430 Milk Thistle
biliary secretion of the hepatoprotective bile salts b-muricholate
and ursodeoxycholate.

Figure 1 Selected constituents properties Silibinin injected into rats prior to

Nephroprotective
of milk thistle.
administration of cisplatin afforded protection of glomerular and
(18, 19)
Dosage proximal tubular function. Silibinin doesacceleration
esis and not affectof the
liver regeneration. S
(19)
cytotoxic activity of cisplatin. Intraperitoneal silibinin (5 mg/
mixture comprising mainly silibinin, silichris
Dosages for oral administration (adults) for traditional uses
kg) administered to rats 30 minutes before ciclosporin decreased
recommended in standard herbal reference texts are given below. the pharmacologically active component of
ciclosporin-induced lipid peroxidation but produced
silibinin is theno protective
main component of silymarin.
Fruit Crude drug 12–15 g effect ondivided
daily in M
the glomerular
(G3)
(20)
filtrationtorate. literature on the pharmacological effects
doses (equivalent
silymarin 200–400 mg daily). silibinin, particularly with regard to the
Anticancer activity Silybin at concentrations of 0.1–20
activity which mmol/L
provides supporting evidence
Herb Approximately 1.5 g of finely chopped material as a tea, two
inhibited the growth of drug-resistant The ovarian cancer cells
pharmacology and and
clinical efficacy of m
or three cups daily. (21)
(1–3, G50, G55)
doxorubicin-resistant breast cancer cellsreviewed.
Figure 1
The doses of silymarin used in clinical trials have ranged from
Selected in vitro. Furthermore,
constituents of milk thistle. The following represe
280–800 mg/day (equivalent silybin
to milkinthistle
the range
extractofDosage
0.1–1.0mg/
400–1140 potentiated
mmol/L selected the effect
publications of subject.
on this
esis
cisplatin and doxorubicin
day standardised to contain 70% silibinin). Dosages(3) in experimental
For hepatic There
tumour is a
celllack of
lines. research
When investigating
mixt
t
for oral administration (adults) for traditional uses (G2
applied
disorders, doses of up to 140 to the skin
mg (equivalent to of SENCAR
60 mg silibinin)mice, effects
silymarinof preparations
gave protection of milk thistle leaf.the
recommended in standard herbal reference texts are given below.
two or three times daily have against the effects
been suggested. of the tumour promoters 12-O-tetradecanoyl-
(G43) silib
Fruit Crude drug 12–15(22) g daily in divided doses (equivalent to liter
In Germany, the recommended phorbol (TPA)regimenand forokaidic acid
treatment (OA).
of In Topical
(G3)andapplication
vitro
silymarin 200–400 mg daily). animal of
studies silib
igure 2 Milk thistle (Silybum marianum). Amanita phalloides poisoning silymarin
with prior to that of
a standardised TPA and OA completely inhibited
silymarin
M
Silybum marianumpreparation (Legalon) is a total induction of tumour necrosis
dose of silibinin (as
Herb Approximately 1.5 g of finely chopped material as a tea, two
the factor
disodium
or three cups a (TNFa) mRNA expression
daily.
Antioxidant activity Silymarin and
activ
sil
The
ow-density lipoprotein (LDL) in vitro dihemisuccinate)
in a concentration- (20 mg/kg in
body
the weight) overSubstantial
epidermis. 24 hours, divided
protection
The doses antioxidants
from
of silymarin thattrials
reacthave
photocarcinogenesis
used in clinical with freefrom
ranged radicals (
revie
(10)
thistle Barnes, selec
ependent manner. Silybin appears to beintothefour
constituent
(G43, G55)
of infusions
intravenous in miceeach givenwith
treated over a 2-hour
phorbol
280–800 mg/dayester species) transforming
or 7,12-dimethylbenz(a)
(equivalent to milk
(1, 4–6)
them
extract 2007
into
400–1140 more stab
mg/
T
lymarin responsible for the LDL antioxidant period.
Figure 1effect. In constituents
contrast,of milkanthracene day standardised(23)tocompounds.
has been demonstrated. contain
The antitumour Silymarin
effect isForand
70% silibinin). (3)
silybin hav
hepatic
Selected thistle.
disorders, doses of up to 140 mg (equivalent to 60 mg silibinin) effec
lichristin and silydianin appeared to act as pro-oxidants, but inihibit
primarily at stage 1 tumour promotion and silymarin acts lipid peroxidation
(G43) by
induced by iron-li
 PLANTAS"MEDICINAIS"
(Lei"5991/1973)"

Uso"não"medicinal" Uso"medicinal"
DROGAS"VEGETAIS"

DERIVADO(VEGETAL( Uso"medicinal"
Chás" (EXTRATOS)(
alimenLcios" Chás"
(RDC(27/2010;( medicinais"
RDC(219/2006;(
RDC(267/2005;(
FITOTERÁPICO( (RDC"26/2014)"
RDC(277/2005(

MANIPULADO" INDUSTRIALIZADO(

MEDICAMENTO( PRODUTO(
( FARMÁCIAS( FITOTERÁPICO( TRADICIONAL(
FARMÁCIAS(DE( VIVAS((RDC" (REGISTRO"COMUM" FITOTERÁPICO(
MANIPULACÃO( 18/2013)" OU"SIMPLIFICADO)" (REGISTRO"
(RDC"67/2007"/" (RDC"26/2014)" SIMPLIFICADO"OU"
87/2008)" NOTIFICADO)"
(RDC"26/2014"e" 3"
IN"02/2014)"
 BIOMEDICINA NUTRIÇÃO
RE CFBM 241/2014
RE CFN 525/2013
RE CFN 556/2015

ODONTOLOGIA
RE CFO 82/2008
FARMÁCIA
RE CFF 585/2013
FITOTERAPIA RE CFF 586/2015

FISIOTERAPIA
RE COFFITO 380/2010

ENFERMAGEM
RE COFEN 197/1997
MEDICINA
CRITÉRIOS BÁSICOS PARA PRESCRIÇÃO (NUTRICIONISTAS)

• Estratégia complementar à prescrição dietética;

• Exclusivamente por via oral;

• Isento de prescrição médica;

• Com indicações relacionadas à área de atuação do nutricionista;

• Não associado com suplementos ou outras substâncias isoladas;

• Fundamentadas em evidências científicas de eficácia e segurança ou

por tradicionalidade de uso comprovada;

• A PARTIR DE 2018: Prescrição de derivados de droga vegetal se dará

somente com obtenção de título de especialista

RE CFN 525/2013; RE CFN 556/2015; RE CFN 334/2004

CRITÉRIOS BÁSICOS PARA PRESCRIÇÃO POR NUTRICIONISTAS

Medicamentos fitoterápicos
Produtos tradicionais fitoterápicos
Preparações magistrais fitoterápicas

Título de especialista em
Nutrição em fitoterapia (Asbran)

RE CFN 525/2013; RE CFN 556/2015; RE CFN 334/2004

SELEÇÃO DE FITOTERÁPICOS PARA A PRÁTICA DA PRESCRIÇÃO

Planta medicinal/
fitoterápico Relação de doenças

X
Relação de plantas
Doença medicinais/
fitoterápicos
Blumenthal, 1998
 tempo de uso na literatura técnico-científica. Para serem disponibilizados ao consumo, tanto o MF
quanto o PTF terão que apresentar requisitos semelhantes de qualidade, diferenciando-se nos
requisitos de comprovação da segurança e eficácia/efetividade, bulas/folheto informativo,
SELEÇÃO DE FITOTERÁPICOS PARA A PRÁTICA DA PRESCRIÇÃO
embalagens, restrição de uso e de Boas Práticas de Fabricação e Controle (BPFC) (Quadros 1 e 2).

Quadro 1 - Diferenças entre os fitoterápicos tratados pela RDC nº 26/2014

Diferenças
Comprovação de Segurança e
Eficácia/Efetividade (SE)
Boas Práticas de Fabricação
(BPF)
Informações do fitoterápico para
o consumidor final
Formas de obter a autorização
de comercialização junto à
Anvisa
Medicamento Fitoterápico Produto Tradicional Fitoterápico
(MF) (PTF)
Por estudos clínicos Por demonstração de tempo de uso
Segue a RDC nº 17/2010 Segue a RDC nº 13/2013
Disponibilizadas na Bula Disponibilizadas no Folheto
informativo
Registro ou Registro, Registro simplificado ou
Registro simplificado Notificação

Quadro 2- Semelhanças entre os fitoterápicos tratados pela RDC nº 26/2014

Medicamento Fitoterápico (MF) Produto Tradicional Fitoterápico (PTF)
Semelhanças Requisitos de Controle de Qualidade (CQ)
Controle do Insumo Farmacêutico Ativo Vegetal (IFAV)

IN 04/2014,
11 ANVISA
REFERÊNCIAS CONFIÁVEIS EM FITOTERAPIA

• Literatura reconhecida pela ANVISA (RDC 26/2014)

• RDC 10/2010 (chás medicinais)

• Natural Medicines Database

(naturalmedicines.therapeuticresearch.com)

• Examine Database (http://examine.com/)

LITERATURA RECONHECIDA

I]^gY
ZY^i^dc

=ZgWVaBZY^X^cZh
?dVccZ7VgcZh!A^cYV66cYZghdc
VcY?9Vk^YE]^aa^ehdc
=ZgWVabZY^X^cVaegdYjXihVgZ^cXgZVh^c\^cedejaVg^in^ci]ZYZkZadeZYldgaYVcYXdci^cjZidWZVc
=ZgWVaBZY^X^cZh
^bedgiVci]ZVai]XVgZVeegdVX]^cYZkZade^c\Xdjcig^Zh#=dlZkZg!Vadc\h^YZi]Zl^YZhegZVYjhZd[]ZgWVa
bZY^X^cZh!i]ZgZVgZbVcnXdcXZgchVWdjii]Z^gfjVa^in!hV[ZinVcYZ[ÄXVXn#=ZgWVaBZY^X^cZhegdk^YZh
VXdbegZ]Zch^kZh^c\aZhdjgXZd[hX^Zci^ÄXVaang^\dgdjh!^beVgi^Va^c[dgbVi^dcdcdkZg&*%d[i]Zbdhi
XdbbdcanjhZY]ZgWVabZY^X^cVaegdYjXih#I]^hi]^gYZY^i^dc]VhWZZcZmiZch^kZangZk^hZYVcYjeYViZY#
I]^gYZY^i^dc
;ZVijgZh^cXajYZ/
™ ;jaaXdadjgi]gdj\]dji!l^i]X]Zb^XVahigjXijgZhVcYe]did\gVe]hd[i]ZeaVciVcYXgjYZYgj\
bViZg^Va
?dVccZ7VgcZh!A^cYV66cYZghdc
™ &*'bdcd\gVe]h!XdbegZ]Zch^kZangZ[ZgZcXZY!YZiV^a^c\e]nidX]Zb^XVa!e]VgbVXdad\^XVaVcY
Xa^c^XVaVheZXihd[ZVX]]ZgWjhZh!YdhV\Z!Zk^YZcXZd[Z[ÄXVXn!VYkZghZZ[[ZXih!XdcigV^cY^XVi^dch!
VcY?9Vk^YE]^aa^ehdc
jhZ^cegZ\cVcXnVcYaVXiVi^dc!Ygj\^ciZgVXi^dch!ZiX#
™ CZlbdcd\gVe]hdcWjiiZgWjgEZiVh^iZh]nWg^Yjh!\gZViZgXZaVcY^cZ8]Za^Ydc^jbbV_jh!`VkV
 E^eZgbZi]nhi^XjbVcYg]dY^daVG]dY^daVgdhZV
™ Bdcd\gVe]hdcVgdjcY'%bV_dg]ZgWVabZY^X^cZhhjWhiVci^VaangZk^hZY!^cXajY^c\ZX]^cVXZV!
ZkZc^c\eg^bgdhZ!\^c`\d!\^chZc\!Hi?d]c¼hldgiVcYkVaZg^Vc
™ EgdYjXi^c[dgbVi^dc[gdbdkZg(%Xdjcig^Zh^cXajY^c\6jhigVa^V!<ZgbVcn!J@VcYJH6#
Lg^iiZcWnZmeZgih^ci]ZÄZaYhd[e]VgbVXd\cdhn!e]nidX]Zb^hign!e]nide]VgbVXn!Xa^c^XVa]ZgWVa
bZY^X^cZh!e]nide]VgbVXdk^\^aVcXZVcYgZ\jaVi^dcd[]ZgWVabZY^X^cVaegdYjXih!=ZgWVaBZY^X^cZh^hVc
^ckVajVWaZgZ[ZgZcXZiZmi[dge]VgbVX^hihVcYdi]Zg]ZVai]XVgZegd[Zhh^dcVahl]dgZfj^gZZk^YZcXZ"WVhZY
^c[dgbVi^dcdc]ZgWVabZY^X^cZhjhZY[dgigZVibZciVcYegZkZci^dcd[]ZVai]egdWaZbh#
;gdbi]ZgZk^Zlhd[egZk^djhZY^i^dch
»I]^h\daYb^cZd[Vji]Zci^X\j^YVcXZXVccdiWZ[VjaiZY#¼   I]Z>cYjhig^VaE]VgbVX^hi

E]^aa^ehdc
6cYZghdc
7VgcZh
»°I]^h^hdcZd[i]ZWZhiZmVbeaZhhd[Vgd[VjhZ[ja\j^YZ[dge]nh^X^VchVcYXa^c^XVa]ZgWVa^hih°¼
I]Z6bZg^XVc=ZgW6hhdX^Vi^dc
»>i]dgdj\]angZXdbbZcYi]^hiZmi[dgVcndcZ^ckdakZY^ci]ZjhZd[]ZgWVabZY^X^cZh!eVgi^XjaVgane]VgbVX^hih
VcYdi]Zg]ZVai]XVgZegd[Zhh^dcVah^ckdakZY^ci]ZjhZhd[]ZgWh[dgbZY^XVaigZVibZcih#¼
8dbeaZbZciVgnI]ZgVe^Zh^cCjgh^c\VcYB^Yl^[Zgn
?dVccZ7VgcZh^h6hhdX^ViZEgd[Zhhdg^c=ZgWVaBZY^X^cZh!HX]ddad[E]VgbVXn!;VXjaind[BZY^XVaVcY=ZVai]
HX^ZcXZh!Jc^kZgh^ind[6jX`aVcY!CZlOZVaVcY0A^cYV66cYZghdc^hEg^cX^eVaE]VgbVXZji^XVa6hhZhhdg!
BZY^X^cZh=ZVai]XVgZegdYjXihGZ\jaVidgn6\ZcXn!AdcYdc!J@0?9Vk^YE]^aa^ehdc^h:bZg^ijhEgd[Zhhdg!
8ZcigZ[dgE]VgbVXd\cdhnVcYE]nidi]ZgVen!HX]ddad[E]VgbVXn!Jc^kZgh^ind[AdcYdc!J@

lll#e]VgbegZhh#Xdb

6ahdVkV^aVWaZdca^cZ
lll#bZY^X^cZhXdbeaZiZ#Xdb
QUAL O REFERENCIAL TEÓRICO PARA A PRESCRIÇÃO DE FITOTERÁPICOS?

Evidências científicas Tradicionalidade de uso

Revisões sistemáticas com meta-análise de estudos Literatura oficialmente reconhecida
clínicos ou monografias de bases de dados
(RDC 26/2014)
especializadas
- Monografias da OMS
Estudos clínicos (randomizados, duplo-cegos,
placebo-controlados) isolados - Literatura secundária técnica

Revisões sistemáticas com meta-análise de estudos - Monografias de farmacopeias

observacionais (coorte)

Estudos observacionais isolados

Séries ou relatos de casos

Opiniões de especialistas
 FITOTERAPIA NA PRÁTICA CLÍNICA

Análise dos recursos Orientação

terapêuticos disponíveis de uso
Avaliação Prescrição Intervenção
• Risco x benefício
• Custo x benefício

Revisão da
terapêutica Follow-up

Objetivo
não alcançado

Êxito Reavaliação
terapêutico Objetivo
alcançado
EXEMPLOS DE ESPÉCIES VEGETAIS
DE INTERESSE TERAPÊUTICO
CAMELLIA SINENSIS

▪ Epigalocatequina Galato (EGCG)

▪ Epicatequina Galato (ECG)
Composição bioativa ▪ Epigalocatequina (EGC)
▪ Epicatequina (EC)
▪ Ácido gálico

Dosagem de catequinas 125 a 625 mg/dia

CAMELLIA SINENSIS

Med Chem Res (2012) 21:3347–3360

CAMELLIA SINENSIS
CAMELLIA SINENSIS

British Journal of Nutrition (2011), 106, 1297–1309

CAMELLIA SINENSIS

British Journal of Nutrition (2011), 106, 1297–1309

CAPSICUM ANNUUM

Composição bioativa Capsinoides

▪ Capsiate
▪ Di-hidrocapsiate
▪ Nor-di-hidrocapsate
Dosagem de capsinoides 6 a 12 mg/dia
CAPSICUM ANNUUM
CAPSICUM ANNUUM
Curr Opin Lipidol 2013, 24:71–77
FIGURE 1. Mean (6SEM) DEE before (0 h) and after oral ingestion of 9 mg capsinoids (d) and placebo (s) in all subjects
(A; n = 18), in BAT-positive subjects (B; n = 10), and in BAT-negative subjects (C; n = 8) and DEE during a 1-h period
after ingestion of capsinoids (D; closed columns) and placebo (open columns), calculated as the AUC between 0 and 1
h. ANOVA showed significant effects of time (P < 0.001), capsinoids x BAT (P = 0.03), and time x capsinoids · BAT (P =
0.046) in B and C. aSignificantly different from 0 h, P < 0.05. bSignificantly different from placebo, P < 0.05. cSignificantly
different from BAT-negative group given capsinoids, P < 0.05. BAT, brown adipose tissue; BAT+, BAT-positive; BAT–,
BAT-negative; EE, energy expenditure; DEE, change in energy expenditure.

Am J Clin Nutr 2012;95:845–50.

Intervenção: 9 mg de capsinoides totais
GARCINIA CAMBOGIA

Composição bioativa ▪ Ácido Hidroxicítrico (HCA)

▪ Cambogim
▪ Camboginol
▪ Bioflavonóides, xantonas, benzofenonas
▪ Antocianidinas

Dosagem de ácido hidroxicítrico 600 a 1.200 mg/dia

GARCINIA CAMBOGIA

Br J Nutr. 2009 Jun;101(12):1867-77

GARCINIA CAMBOGIA

J Obesity 2011; doi:10.1155/2011/509038

GARCINIA CAMBOGIA

J Obesity 2011; doi:10.1155/2011/509038

GARCINIA CAMBOGIA

J Obesity 2011; doi:10.1155/2011/509038

 IRVINGIA GABONENSIS

Não disponível
Composição bioativa Erroneamente anunciado como mangiferina
(Mangifera indica)

IGOB131 (princípios ativos não declarados nos estudos).

Dosagem do extrato
150 mg x 1.050 mg
IRVINGIA GABONENSIS

Lipids in Health and Disease 2009, 8:7-15

IRVINGIA GABONENSIS

Lipids in Health and Disease 2009, 8:7-15

IRVINGIA GABONENSIS

Lipids in Health and Disease 2009, 8:7-15

IRVINGIA GABONENSIS
The efficacy of Irvingia gabonensis supplementation in the management of overweight
and obesity: a systematic review of randomized controlled trials.

Onakpoya I, Davies L, Posadzki P, Ernst E.

The aim of this systematic review was to evaluate the evidence from randomized controlled trials (RCTs)
involving the use of the African Bush Mango, Irvingia gabonensis for body weight reduction in obese and
overweight individuals. Electronic and nonelectronic searches were conducted to identify relevant RCTs.
The bibliographies of located articles were also searched. No age, gender, or language restrictions were
imposed. The reporting quality of identified RCTs was assessed using a methodological checklist adapted
from the Consolidated Standard of Reporting Trials Statement and Preferred Reporting Items for
Systematic Reviews and Meta-analyses guidelines. Two reviewers independently determined eligibility and
assessed the reporting quality of included studies. Three RCTs were identified, and all were included. The
RCTs all had flaws in the reporting of their methodology. All RCTs reported statistically significant
reductions in body weight and waist circumference favoring I. gabonensis over placebo. The results from
the RCTs also suggest positive effects of I. gabonensis supplementation on the blood lipid profile. Adverse
events included headache and sleep difficulty. Due to the paucity and poor reporting quality of the RCTs,
the effect of I. gabonensis on body weight and related parameters are unproven. Therefore, I. gabonensis
cannot be recommended as a weight loss aid. Future research in this area should be more rigorous and
better reported.
J Diet Suppl. 2013 Mar;10(1):29-38.
AMORPHOPHALLUS KONJAC (GLUCOMANAN)

Composição bioativa Polímeros de glicose e manose

Dosagem de fibras totais 500 a 4.000 mg/dia

AMORPHOPHALLUS KONJAC (GLUCOMANAN)
• Promove aumento da saciedade (pela redução do esvaziamento
gástrico, do trânsito intestinal), da excreção calórica pelas fezes, além
de melhorar o perfil glicêmico e lipídico (reduz a biodisponibilidade de
gorduras e açúcares provenientes da dieta)
• Evidências científicas sugerem doses de 2 a 4g ao dia promovem
redução de peso em indivíduos sobrepesados ou obesos e melhora o
perfil glicêmico e lipidêmico, com baixa frequência de efeitos adversos,
em adultos e crianças

Altern Ther Health Med; 2005; 11: 30–34

Metab Clin Exper; 2007; 56: 1149–1158
ure, platelet aggre- Traditionally, it has been used to treat chronic bronchitis,
sures of peripheral respiratory catarrh, recurrent colds, whooping cough, bronchitic
ed the administra- asthma, influenza and chronic bronchitis.(G2, G6, G32, G34, G49, G64)
G Modern use of garlic and garlic preparations is focused on their
reputed antihypertensive, anti-atherogenic, antithrombotic, anti-
antihypertensive, lipid-lowering, anti-atherogenic, antithrombo-
tic, fibrinolytic, antioxidant, anticarcinogenic, antitumorigenic,
immunomodulatory and antimicrobial activities. The pharmaco-
logical properties of garlic are attributed mainly to its sulfur-
containing compounds. An extensive review of the pharmacolo-

ALLIUM SATIVUM microbial, fibrinolytic, cancer preventive and lipid-lowering

effects.
gical properties of garlic and its constituents is beyond the scope
of this monograph, although many studies are summarised below.

Dosage
Dosages for oral administration (adults) for traditional uses
Figure 2 recommended in standard herbal and older pharmaceutical
Garlic (Allium sativum).
reference texts are given below.
Dried bulb 2–4 g three times daily;(G6) fresh garlic 4 g daily.(G3)
Tincture 2–4 mL (1 : 5 in 45% alcohol) three times daily.(G6)
Oil 0.03–0.12 mL three times daily.(G6)
Juice of Garlic (BPC 1949) 2–4 mL.(G11)
Syrup of Garlic (BPC 1949) 2–8 mL.(G11)
Clinical trials assessing the effects of garlic powder tablets on
various parameters, including total serum cholesterol concentra-
tions, triglyceride concentrations, blood pressure, platelet aggre-
gation, vascular resistance, fibrinolysis and measures of peripheral
arterial occlusive disease, have generally involved the administra-

Figure 3 Garlic – dried drug substance (bulb).

Figure 2 Garlic (Allium sativum).

Óleos voláteis: compostos organossulfurados (alicina,

Composição bioativa
aliina, alilpropil dissulfito, ajoeno, dialil dissulfido)

Dosagem do
3 a 5 mg de alicina
marcador

Figure 1 Selected constituents of garlic. Figure 3 Garlic – dried drug substance (bulb).
 Juice of Garlic (BPC 1949) 2–4 mL.
Syrup of Garlic (BPC 1949) 2–8 mL.(G11)
Clinical trials assessing the effects of garlic powder tablets on
ALLIUM SATIVUM
various parameters, including total serum cholesterol concentra-
tions, triglyceride concentrations, blood pressure, platelet aggre-
gation, vascular resistance, fibrinolysis and measures of peripheral
arterial occlusive disease, have generally involved the administra-

Figure 2 Garlic (Allium

Figure 1 Selected constituents of garlic. Figure 3 Garlic – dried

ALLIUM SATIVUM
• Uso tradicional reconhecido em doenças cardiovasculares:

• Antihipercolesterolêmico
• Anti-hipertensivo leve
• Anticoagulante plaquetário
• Tônico vascular
Alho fresco 2-4g ao dia
Tintura (1:5, 45% de etanol) 2 a 4 mL , 3x ao dia

Suco 2 a 4 mL ao dia

Barnes, 2007
 tion-dependent inhibition of de novo cholesterol biosynthesis in
of 6 g drug, or artichoke leaf, dose
an equivalent including inhibition
of extract (basedofoncholesterol
the herb-to-biosynthesis,
hypolipidaemic, antioxidant and hepatoprotective cultured rat and human hepatocytes for globe artichoke leaf
extract ratio) or other preparations, for dyspeptic problems.(G3,activity. It (15)
G56) remains unclear which of the constituents of artichokeextract are 0.03–0.1 mg/mL.
A recommended dosage regimen for liquid extract (1 : 2) is 3–
responsible for its pharmacological activities. The dicaffeoylquinic Several other experimental studies have documented lipid-
8 mL daily.(G50)acids, which include cynarin, are likely to be an important group
CYNARA SCOLYMUS
Dosages used in clinical trials of globe
of constituents in this respect.
have assessed the
sucheffects of dosages of
as cynaropicrin,
(12)
artichoke
(11, G50)

andupflavonoids,
leaf extract
lowering effects for globe artichoke leaf extract and cynarin in
vivo.(10, 11) A study in rats explored the hypocholesterolaemic,
The sesquiterpene lactones,
to 1.92 g daily in luteolin
such as divided glycoside,
hypolipidaemic and choleretic effects of purified (containing 46%
doses for up tomaysixalso
months.
exert biological effects.(11) caffeoylquinic acids, calculated as chlorogenic acid) and total
extracts of globe artichoke leaf (containing 19% caffeoylquinic
Pharmacological Actions
Several pharmacological properties have been documented for
artichoke leaf, including inhibition of cholesterol biosynthesis,
hypolipidaemic, antioxidant and hepatoprotective activity. It
remains unclear which of the constituents of artichoke are Figure 3 Artichoke.
responsible for its pharmacological activities. The dicaffeoylquinic
acids, which include cynarin, are likely to be an important group
of constituents in this respect.(11, G50) The sesquiterpene lactones,
such as cynaropicrin, and flavonoids, such as luteolin glycoside,
may also exert biological effects.(11)

Figure 3 Artichoke.

Figure 2 Artichoke (Cynara scolymus). Figure 4 Artichoke – dried drug substance (leaf).

Ácidos orgânicos: ácidos fenólicos, ácido clorogênico, ácido

Composição bioativa cafeico, cinarina.
Flavonóides: Glicosídeos flavônicos (luteonina-7ß-rutinosídeo)

Dosagem do 24 a 48 mg de derivados de ácido cafeoilquínico

marcador expressos em ácido clorogênico
 lobe artichoke should not be confused with Jerusalem
developed fruits and flowers are devoid of cynaropicrin; highest
hoke, which is the tuber of Helianthus(6)tuberosus L.
content reported in young leaves.

CYNARA SCOLYMUS
t(s) Used
Food Use
Artichoke is listed by the Council of Europe as a natural source of
food flavouringand
armacopoeial (category N2). This category indicates that
Other Monographs
artichoke
1996(G9) can be added to foodstuffs in small quantities, with a
possible
007(G84) limitation of an active principle (as yet unspecified) in the
mplete German Commission E(G3)
tindale 35th edition(G85)
Eur 2007(G81)

al Category (Licensed Products)

(G37)

nstituents
following is compiled from several sources, including
rences 1 and 2, and General Reference G41.
s Phenolic, up to 2%. Caffeic acid, mono- and dicaffeoyl-
ic acid derivatives, e.g. cynarin (1,5-di-O-caffeoylquinic acids)
chlorogenic acid (mono derivative).
onoids 0.1–1%. Flavone glycosides, e.g. luteolin-7b-rutino-
(scolymoside), luteolin-7b-D-glucoside and luteolin-4b-D-
oside. Figure 1 Selected constituents of artichoke.

67
CYNARA SCOLYMUS
• Uso tradicional reconhecido em:

• Dispepsia funcional
• Hipercolesterolemia leve a moderada

• Evidências mostram benefícios na detoxificação hepática.

Extrato líquido (1:2) 3 a 8 mL ao dia

Barnes, 2007
 MODELOS DE
PRESCRIÇÕES
Chás e extratos secos
padronizados
Dr. Leandro Medeiros
Farmacêutico • CRF-PE: 3478

Para: (Nome do paciente)

Rx:
Allium sativum (alho) …. droga vegetal do bulbo

Modo de preparo:

• Cobrir o conteúdo de 1 colher de café rasa em 30 mL de água

• Deixar em temperatura ambiente por 1 hora
• Agitar ocasionalmente e coar

Tomar 1 cálice (30 mL), 2x/dia, antes das refeições, por 3 meses.
Não repetir receita.
Dr. Leandro Medeiros
Farmacêutico • CRF-PE: 3478

Para: (Nome do paciente)

Rx:
Allium sativum (extrato seco, 5% de alicina) 50 mg
Camellia sinensis (extrato seco, 50% de polifenois 250 mg
totais)
Aviar em cápsulas 120 doses

Tomar 1 cápsula, 2x ao dia, após as refeições, por 3 meses.

Não repetir receita.
DÚVIDAS?
 Obrigado!

Instagram/Snapchat: @prof_leandromedeiros
E-mail: leandro.a.medeiros@gmail.com
Facebook: @leandro.a.medeiros

www.facebook.com/groups/falandosobrefitoterapia/